Pharma Plant Setup Cost Calculator
Estimate what a pharmaceutical manufacturing plant actually costs in India — section by section, at your capacity, under Revised Schedule M, WHO-GMP, EU-GMP or USFDA. Then see the same plant priced across all four standards at once.
Which standard is the plant being built to?
This is the single biggest cost driver — bigger than capacity. A WHO-grade compression machine costs around ₹10 lakh; a USFDA-compliant equivalent runs into crores. Cleanroom finish, AHU specification and laboratory instrumentation all step up with it.
Which sections, and at what capacity?
Each section is a complete package — machinery, its dedicated AHU, and its classified area. Capacity scales machinery at the observed rate: doubling output adds roughly 40%, because only higher-capacity machines change, not the whole line.
Site, land and support areas
Land rates below are greenfield agricultural rates requiring conversion to industrial use. CLU charges are added at 5% of land value; site development is already inside the construction rate.
Financial assumptions
Same plant, four standards
Identical sections and capacities, priced under each compliance grade (excluding land).
Cost breakdown — tap any line for detail
Download your detailed project report
Line-item PDF · reviewed by our team
Report ready — your print / save-as-PDF dialog should open.
Please enter your name and phone number.
We use these details only to send your report and answer questions about it.
How to read this estimate. Figures are built from Laafon Galaxy's own project cost basis — section packages at reference capacity, scaled to yours, with civil, utility and laboratory rates applied per compliance grade. Actual quotations vary with vendor selection, imported versus domestic equipment, site conditions and procurement timing. Use this to size funding and compare configurations; commission a Detailed Project Report before committing capital.
What actually drives pharma plant cost in India?
Most published estimates fail because they treat compliance grade as a footnote. In practice it outweighs capacity, location and even dosage form.
Compliance standard is the dominant variable
The same plant — same sections, same capacity, same state — can differ by more than four times purely on the standard it is built to. A tablet compression machine acceptable under WHO-GMP costs roughly ₹10 lakh; a USFDA-compliant machine, with the required materials of construction, control systems and documentation, can cost crores. That multiple repeats across every machine, every AHU and every laboratory instrument.
Cleanroom civil rates escalate the same way: approximately ₹2,500 per sq ft for a Revised Schedule M finish, ₹3,000 for WHO-GMP and ₹5,000 for EU-GMP, higher again for USFDA. Laboratory instrumentation moves from around ₹1.5 crore for a Schedule M or WHO unit to ₹6 crore and upward for EU or USFDA — instruments alone, before furniture.
This is why the four-standard comparison exists on this page. Building export-grade is a capital decision worth modelling before it is made, not after.
Capacity matters less than most people expect
Doubling output does not double machinery cost. Beyond a base configuration, only the higher-capacity machines change — the rest of the line, the AHU and most of the classified area stay as they are. The observed increase is roughly 20–40% for a doubling of capacity, which the calculator applies as a scaling curve rather than straight multiplication.
The practical implication: if you are choosing between 5 lakh and 10 lakh tablets per day, the larger line is almost always better on cost per unit — provided the market absorbs the output.
Section packages, not machine lists
Each section carries three linked costs: machinery, its dedicated AHU, and its classified area. A tablet section at 5 lakh/day needs about 7,000 sq ft classified; capsules at the same output about 4,000; liquid orals around 7,000; dry syrup 3,000; ointments and creams 2,500; and sterile injectables about 5,000 sq ft with a far heavier machinery and AHU load. Beta-lactam tablet sections match non-beta on machinery but need a heavier dedicated AHU, because segregation is non-negotiable.
Worked examples
Calculated on the model this page runs, excluding land so they stay comparable:
And the comparison that matters most — one plant (tablets plus capsules, Himachal Pradesh, excluding land) across all four grades:
The step from Schedule M to WHO-GMP is modest — largely AHU specification and cleanroom finish. The step to EU or USFDA is a different order of investment, and should be underwritten by a committed export order book rather than optimism.
Land is smaller than most promoters assume
Greenfield land requiring industrial conversion runs roughly ₹150–400 per sq ft across the main pharma states — Himachal Pradesh (Baddi, Solan, Una) and Uttarakhand (Haridwar, Roorkee) around ₹300, Gujarat lower, Haryana higher. CLU charges add about 5% of land value. On most projects land is under 10% of total cost — which is why optimising location for vendor access and skilled manpower usually beats optimising for cheap land.
What sits outside this estimate
The calculator covers capital cost to commissioning plus a six-month working capital float. It does not model revenue, break-even or loan servicing. For funding structure, subsidies and payback expectations, read how much investment is needed to start a pharma manufacturing plant. If your unit already exists and needs upgrading rather than building, the Revised Schedule M compliance dashboard tracks what enforcement now requires. And if buying is faster than building, compare verified plants for sale and rent.
Pharma plant cost, answered.
How much does it cost to set up a pharma plant in India?
A single tablet section at 5 lakh tablets per day, built to Revised Schedule M, works out to roughly ₹7–8 crore excluding land. A three-section WHO-GMP unit lands near ₹15 crore, and a sterile injectable facility at EU-GMP around ₹25 crore. USFDA-grade builds start far higher, because machinery and instrumentation costs multiply rather than merely increase.
Why does a USFDA plant cost so much more than a Schedule M plant?
Because the equipment itself is different, not just the paperwork. A compression machine acceptable under WHO-GMP may cost ₹10 lakh, while a USFDA-compliant machine can cost crores — driven by materials of construction, control systems, data integrity capability and documentation. Multiply that across every machine, AHU and laboratory instrument and plant cost rises several-fold rather than by a percentage.
Does doubling capacity double the cost?
No. Beyond a base configuration only the higher-capacity machines change — line layout, AHU and most classified area stay the same. The observed increase is roughly 20–40% for a doubling of output, which usually makes the larger line better on cost per unit if demand supports it.
How much land is needed, and is it included?
Land area follows built-up area divided by permissible ground coverage, typically 45%. You choose whether to include it. Rates default to greenfield agricultural land requiring industrial conversion, with CLU charges added at 5% of land value.
What is not included in this estimate?
Capital cost to commissioning and a six-month working capital float are included. Revenue projections, break-even analysis, loan servicing and product-specific costs such as API procurement are not — those belong in a Detailed Project Report prepared against your product portfolio.
Turn this estimate into a fundable project plan.
Detailed Project Report, layout review, equipment specification and the licensing pathway for your chosen state.